Czechia· CZ-0286444
EXDENSUR
A depemokimab product containing depemokimab, registered in Czechia by GlaxoSmithKline Trading Services Limited, Dublin. The same ATC class is registered in 9 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Depemokimab is registered in 9 of 19 countries.
Countries holding a registration under ATC R03DX12 (depemokimab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 5 of them publish a price we can compare per daily dose
Depemokimab · ATC R03DX12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- DEPEMOKIMAB
- Manufacturer
- GlaxoSmithKline Trading Services Limited, Dublin
- Country
- Czechia (CZ)
- ATC code
- R03DX12
- ATC class
- Depemokimab
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Depemokimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomExdensur 100mg/1ml solution for injection pre-filled pensGlaxoSmithKline UK Ltd
- PolandExdensurGlaxoSmithKline Trading Services Limited
- SwedenEXDENSUR 100 mg Injektionsvätska, lösning i förfylld injektionspennaGlaxoSmithKline Trading Services Ltd
- SpainEXDENSUR 100 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAGlaxosmithkline Trading Services Limited
- IcelandEXDENSURGlaxoSmithKline Trading Services Limited
- BelgiumExdensur 100 mgGlaxoSmithKline Trading Services
- United StatesExdensurGlaxoSmithKline LLC
- FinlandEXDENSURGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Exdensur
- Liechtenstein · Exdensur
- Norway · Exdensur
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b5f2cb22-31a3-46e2-8705-fee9477e37b0 GET /v1/drugs/b5f2cb22-31a3-46e2-8705-fee9477e37b0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL ISP",
"source": "sukl",
"strength": "100MG",
"pack_size": "1X1ML",
"substance": "DEPEMOKIMAB",
"cz_kod_sukl": "0286444",
"product_type": "BT",
"substance_codes": "22618",
"registration_state": "R",
"registration_number": "EU/1/25/2007/002"
}See everything about depemokimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.